Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy

Andras G. Lacko, Bhalchandra J. Kudchodkar, Wayne W. Loney, Michael B. Clearfield, Stephen Weis

Research output: Contribution to journalArticlepeer-review


This report represents the continuation of our studies on the effects of gemfibrozil therapy on high density lipoprotein cholesterol levels. Previously, we reported that despite an impressive mean increase in high density lipoprotein cholesterol (20%), the response to 12 weeks of gemfibrozil therapy was highly variable. Accordingly, out of the 27 subjects studied, five actually had lower high density lipoprotein cholesterol at the conclusion of therapy compared to baseline values. The changes observed in plasma lipids, combined with correlational relationships suggest that the conversion of triglyceride rich lipoprotein components into high density lipoprotein may be impaired in those subjects that respond poorly or negatively to gemfibrozil therapy.

Original languageEnglish
Pages (from-to)389-392
Number of pages4
JournalClinical Chemistry and Laboratory Medicine
Issue number6
StatePublished - 1998


  • Gemfibrozil therapy
  • High density lipoprotein cholesterol
  • Triglycerides


Dive into the research topics of 'Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy'. Together they form a unique fingerprint.

Cite this